Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03388268 |
| Other study ID # |
201708055 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 4
|
| First received |
|
| Last updated |
|
| Start date |
December 29, 2017 |
| Est. completion date |
January 31, 2021 |
Study information
| Verified date |
July 2021 |
| Source |
Washington University School of Medicine |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to determine the risks and benefits of antibiotic treatment for
Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid
amplification test (NAAT) positive and enzyme immunoassay (EIA) negative for C. difficile.
Currently, healthcare facilities use a wide variety of tests and strategies for identifying
patients with CDI; both EIA and NAAT are widely used. There is no clear gold standard for
identifying CDI. At WUSM and BJH, patients are only treated for CDI if they have a positive
EIA. However, at many other healthcare facilities, the standard of care is to treat for CDI
if the patient is NAAT positive. Some patients who are NAAT-positive may not have true CDI;
while this treatment is standard of care at many facilities, the risk and benefits of
treating these patients for CDI is unknown.
We propose to perform a double blinded, randomized controlled non-inferiority trial of
antimicrobial of patients who are EIA negative, NAAT positive to determine the risks and
benefits of CDI treatment in this population.
Description:
Study Purpose:
The purpose of this study is to determine the risks and benefits of antibiotic treatment for
Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid
amplification test (NAAT) positive and enzyme immunoassay (EIA) negative for C. difficile.
Background:
Clostridium difficile infection (CDI) is the most common cause of healthcare-associated
diarrhea. There is no gold standard diagnostic test for (CDI). Commercially available assays
detect C. difficile or its toxins in stool. Nucleic acid amplification tests (NAAT) are much
more sensitive than toxin enzyme immunoassays (EIA). However, clinical correlation is needed
to determine who has CDI. Most US clinical microbiology laboratories have adopted NAATs for
C. difficile under the presumption the enhanced analytical sensitivity was beneficial.
Although some patients with NAAT-positive/toxin-negative stool have CDI and a false-negative
toxin EIA, subsequent studies indicate most patients with NAAT-positive / toxin-negative
stool do not have CDI. Rather, they are asymptomatic C. difficile carriers who have diarrhea
for other reasons. Most of these studies also have limitations and considerable controversy
remains for whether NAATs or toxin EIAs should be used when CDI is suspected.
Treatment of asymptomatic C. difficile carriers is not beneficial, and may result in harm. At
hospitals that utilize NAATs, most patients with NAAT-positive / toxin-negative stool receive
treatment for CDI. The most common treatments for CDI, metronidazole and oral vancomycin, are
highly disruptive of the intestinal microbiome. These antimicrobials create selective
pressures that promote the acquisition and proliferation of antimicrobial resistance and
multidrug resistant organisms (MDRO), including public health threats such as MDRO
Enterobacteriaceae like carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum
beta-lactamase (ESBL) producing organisms, vancomycin-resistant Enterococcus (VRE), and the
latest emerging threat Candida auris. This leads to MDRO infections and MDRO spread to
others. Paradoxically, unnecessary treatment for CDI may increase risk for CDI once treatment
is stopped contributing to CDI-related adverse events and C. difficile spread to others.
Unnecessary CDI treatment potentially harms both that patient and other people. Whether the
benefit of treating patients with NAAT-positive/toxin-negative stool that are missed cases of
CDI outweighs the risk of treating patients with NAAT-positive/toxin-negative stool that are
asymptomatic C. difficile carriers remains unknown.
This study is a double-blinded randomized controlled trial of CDI treatment for patients with
NAAT-positive / toxin-negative stool. Such a trial is necessary to understand the
risk-benefit of treating these patients for CDI. Patients with NAAT-positive / toxin-negative
stool who consent to participate will be randomized to 10 days of oral vancomycin or placebo.
Stool and environmental specimens will be obtained at regular time points and interrogated
with culturomic and metagenomic methods. Patients will be followed until eight weeks after
discontinuation of study drug. These data and specimens will be used to determine the impact
of oral vancomycin versus placebo on the microbiome, C. difficile and MDRO colonization,
environmental contamination, duration of diarrhea, CDI-related adverse events, and death.
Specific aims and hypotheses:
Specific Aim 1: Determine if there are differences in microbiome disruption and acquisition /
persistence of C. difficile and other MDRO carriage in stool among patients with
NAAT-positive / toxin-negative stool who are randomized to a 10-day course of oral vancomycin
versus placebo.
Hypotheses: Study participants who receive oral vancomycin will have greater disruption of
the taxonomic and functional metabolic profiles of the fecal microbiome, increases in
antimicrobial resistance genes, acquire more MDRO, and will have greater persistence and
abundance of MDRO in stool compared to participants who receive placebo. Participants who
receive oral vancomycin will not have detectable C. difficile in stool after completion of
study drug, but will be more likely to have C. difficile in stool at week 8 after completion
of study drug compared to participants who receive placebo.
Specific Aim 2: Determine if there are differences in C. difficile and other MDRO
environmental contamination between treatment groups.
Hypothesis: Study participants who receive oral vancomycin will have less environmental C.
difficile contamination but more MDRO contamination compared to participants who receive
placebo while receiving study drug. After study drug is completed, those who receive oral
vancomycin will have more environmental contamination due to both C. difficile and other
MDROs.
Specific Aim 3: Determine if there are differences in CDI-related outcomes between groups.
Hypothesis: There will be no difference in time to resolution of diarrhea or CDI-related
outcomes between treatment groups.
